USANA Health Sciences (NYSE:USNA) Stock Rating Upgraded by StockNews.com

USANA Health Sciences (NYSE:USNA) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday.

Separately, DA Davidson raised shares of USANA Health Sciences to a “hold” rating in a report on Friday, December 20th.

USANA Health Sciences Price Performance

USANA Health Sciences stock opened at $35.69 on Friday. The firm has a market capitalization of $680.25 million, a P/E ratio of 12.61, a price-to-earnings-growth ratio of 1.25 and a beta of 0.89. USANA Health Sciences has a 1-year low of $31.44 and a 1-year high of $54.81. The company’s 50-day moving average is $37.88 and its 200 day moving average is $39.89.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, October 22nd. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.49 by $0.07. The company had revenue of $200.22 million for the quarter, compared to the consensus estimate of $208.45 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. During the same quarter last year, the firm posted $0.59 EPS. Research analysts anticipate that USANA Health Sciences will post 2.45 earnings per share for the current fiscal year.

Insider Transactions at USANA Health Sciences

In related news, Director Gilbert A. Fuller sold 675 shares of the business’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $37.71, for a total transaction of $25,454.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.33% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp lifted its stake in shares of USANA Health Sciences by 5.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 97,375 shares of the company’s stock valued at $4,405,000 after purchasing an additional 5,205 shares during the last quarter. Panagora Asset Management Inc. increased its holdings in USANA Health Sciences by 143.1% in the 2nd quarter. Panagora Asset Management Inc. now owns 28,881 shares of the company’s stock valued at $1,307,000 after purchasing an additional 16,999 shares during the last quarter. Rhumbline Advisers raised its position in USANA Health Sciences by 7.1% in the second quarter. Rhumbline Advisers now owns 36,486 shares of the company’s stock valued at $1,651,000 after purchasing an additional 2,425 shares during the period. Pzena Investment Management LLC grew its stake in shares of USANA Health Sciences by 24.4% in the second quarter. Pzena Investment Management LLC now owns 976,633 shares of the company’s stock valued at $44,183,000 after buying an additional 191,289 shares in the last quarter. Finally, TD Asset Management Inc lifted its stake in USANA Health Sciences by 26.4% during the 2nd quarter. TD Asset Management Inc now owns 11,500 shares of the company’s stock worth $520,000 after acquiring an additional 2,400 shares in the last quarter. Institutional investors and hedge funds own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.